Samsung Biologics has launched a new high-concentration formulation platform, dubbed S-HiCon, to support the development and manufacturing of high-dose biopharmaceuticals.
The S-HiCon platform can proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximise drug delivery.
It enables the optimisation of pH, buffer species, and excipients, along with a preliminary ‘Concentration Gate Check’ process.
Also, the platform tests formulation feasibility in the initial stages to identify favourable candidates and minimise potential risks associated with high-concentration development.
Samsung Biologics executive vice president and CDO development head Brian Hosung Min said: “Our new platform will enable us to provide innovative solutions for clients requiring low to ultra-high concentration formulation to develop advanced therapeutics.
“Samsung Biologics is committed to providing customised services by leveraging our expertise and track record in contract development.”
Samsung Biologics is a South Korea-based fully integrated contract development and manufacturing organisation (CDMO), which provides drug development and manufacturing solutions.
Its S-HiCon platform integrates analytical capabilities to address the critical formulation challenges associated with viscosity and protein aggregation.
Samsung Biologics has recorded more than 200mg/mL for liquid formulations, with adequate viscosity and improved stability.
The CDMO service provider said that its new S-HiCon platform is part of its continued efforts to provide clients with advanced technologies that enable high-quality development.
Earlier this year, Samsung Biologics partnered with LegoChem Biosciences to develop and manufacture antibodies as a part of the latter’s ADC programme designed to treat solid tumours.
